How to Calculate M-Spike Levels and Interpret Results

An M-spike is measured through a blood test called serum protein electrophoresis (SPEP), where the lab separates your blood proteins by electrical charge and identifies an abnormal, narrow peak produced by a single clone of plasma cells. The height and area of that peak translate into a concentration, reported in grams per deciliter (g/dL), and tracking that number over time is how doctors gauge whether a plasma cell disorder is stable, worsening, or responding to treatment. The calculation itself happens in the lab, but understanding what the number means and where it can go wrong matters if you or someone you know is living with a monoclonal gammopathy.

How the M-Spike Is Measured

SPEP works by placing a serum sample on a medium and applying an electric field. Proteins migrate at different speeds depending on their size and charge, forming distinct bands. Healthy serum produces a broad, gently curved gamma region because it contains thousands of slightly different immunoglobulins. When a single clone of plasma cells churns out one specific immunoglobulin in large quantities, that protein piles up in one spot and creates a tall, narrow spike on the electrophoresis tracing. That spike is the M-spike (also called the M-band or M-protein peak).

Two main platforms are used in clinical labs. Traditional agarose gel electrophoresis (AGE) has been the workhorse for decades, while capillary zone electrophoresis (CZE) is increasingly common. A comparative analysis found CZE had a sensitivity of about 94% for detecting monoclonal proteins, compared with roughly 88% for AGE, though AGE had a slightly higher specificity at 99.5% versus 98.9% for CZE.¹ In practice, both are considered reliable for initial screening, and your lab’s choice of platform will affect the look of the tracing but not the fundamental principle.

Once the proteins have been separated, the lab uses a densitometer (for gel methods) or software (for capillary methods) to measure the area under the M-spike curve. That area is proportional to the concentration of the monoclonal protein in the serum. The result is typically reported as a number in g/dL, alongside a visual image of the electrophoresis tracing so the ordering physician can see where the spike falls in the protein spectrum. In one study of 150 suspected cases, about 11% showed a monoclonal band on cellulose acetate strip electrophoresis, with densitometric estimation used to quantify the M-protein.²

Two Ways to Quantify the Peak

Here is where the “calculation” part gets interesting, because labs do not all draw the boundaries of the M-spike in the same way. There are two main peak-integration methods, and they can give you meaningfully different numbers from the very same blood sample.

The conventional method is the perpendicular drop (PD). The technologist or software draws vertical lines from the edges of the spike straight down to the baseline and measures everything inside that box. This works well when the M-spike is large and towers above the surrounding normal proteins. The trouble is that the gamma region always contains some background immunoglobulins. PD counts all of those background proteins if they fall within the spike’s boundaries, which inflates the M-protein value.³

The alternative is tangential skim (TS). Instead of dropping vertical lines to the baseline, the technologist draws a curved line that traces the estimated shape of the normal background proteins underneath the spike, then measures only the area above that line. This approach excludes the background, giving a lower and arguably more accurate M-protein concentration. In practice, though, the tangential skim method has not been widely adopted, and its use remains limited.⁴

Why does this matter for you? If the M-spike is small, the difference between the two methods can be proportionally large. A patient with a modest spike might appear to have a significantly higher M-protein by PD than by TS. If you switch labs or your lab changes methods, the numbers may shift even though the disease has not changed. The practical takeaway is to try to have your M-spike tracked at the same lab using the same method over time. Consistency matters more than which method is chosen.

What Immunofixation Adds

SPEP tells you there is a monoclonal protein and roughly how much of it is present, but it does not tell you what kind. For that, the lab runs immunofixation electrophoresis (IFE). This test uses antibodies directed against each type of heavy chain (IgG, IgA, IgM, IgD, IgE) and each type of light chain (kappa and lambda) to identify which immunoglobulin the clone is producing. Identifying the isotype matters because different subtypes behave differently and carry different prognostic implications.⁵

IFE is also more sensitive than SPEP. A small monoclonal protein that does not produce a visible spike on SPEP can sometimes be detected by IFE. This is why treatment response criteria often require both a negative SPEP and a negative IFE before a patient can be classified as having achieved a complete response. Atypical cases underscore IFE’s value. In one report, a patient’s SPEP showed two separate M-bands in different regions, suggesting two different clones. IFE proved both bands were actually the same IgA-kappa protein, migrating in two locations because of the protein’s physical properties rather than true biclonal disease.⁶

Free Light Chain Testing

Not all monoclonal proteins show up well on SPEP. Some plasma cell clones produce only light chains (the smaller portion of the antibody molecule), which are too small and rapidly cleared by the kidneys to accumulate enough in blood for a visible spike. The serum free light chain (sFLC) assay measures kappa and lambda light chains directly and calculates a ratio between them. An abnormal ratio suggests one type is being overproduced.

The sFLC assay is especially valuable for light-chain-only myeloma. In a study comparing monitoring methods, all 25 light-chain myeloma patients had measurable disease by sFLC at diagnosis, while only about a third of intact immunoglobulin myeloma patients had measurable disease by urine electrophoresis, compared with about two-thirds by sFLC.⁷ The sFLC test also provided better sensitivity than urine methods for monitoring treatment response.

One limitation is that sFLC assays are not a perfect substitute for IFE in detecting monoclonal proteins of the full immunoglobulin type. A study comparing the two found that about half of patients with confirmed monoclonal gammopathies by IFE had a normal kappa/lambda ratio on the free light chain assay, and roughly 45% of IgG and IgA M-proteins had a normal ratio.⁸ The tests complement each other rather than replacing one another. A different study evaluating free light chain assays against IFE found the free light chain approach was specific but significantly less sensitive, ranging from about 73% to 91% depending on the light chain type.⁹

Urine Monitoring

Light chains that spill into the urine are historically known as Bence Jones protein, and measuring them through urine protein electrophoresis (UPEP) has long been part of the standard workup. The International Myeloma Working Group and the College of American Pathologists recommend a 24-hour urine collection to determine Bence Jones protein excretion for monitoring treatment response.¹⁰

In practice, though, the 24-hour urine collection is cumbersome. Patients have to collect every drop of urine for a full day, store it properly, and deliver it to the lab. A real-world analysis found that despite guideline endorsement, 24-hour urine tests for UPEP are not used often in routine clinical practice, with collection technique and storage problems limiting their regular use.¹¹ Many clinicians rely more heavily on serum free light chains for routine monitoring, reserving urine studies for specific situations like light-chain myeloma where urine M-spike quantification can provide additional treatment-response data.

Common Lab Pitfalls That Affect Results

Several things can cause a false or misleading M-spike, and knowing about them can save you from unnecessary alarm.

Fibrinogen contamination is one of the most common culprits. If a blood sample is not fully clotted before the serum is separated, residual fibrinogen can create a band in the beta-gamma region that looks like a monoclonal spike. Labs can catch this by checking the gamma-to-IgG ratio or by ordering IFE, which will not confirm a monoclonal protein if the band is fibrinogen.¹²

Intravenous immunoglobulin (IVIG) therapy is another source of false positives. IVIG delivers a large dose of pooled human antibodies, and the concentrated IgG can show up as a discrete band on SPEP. A retrospective study of 348 patients with a history of IVIG found that about 1.4% had an M-spike on SPEP that was not confirmed as a true monoclonal gammopathy by subsequent immunofixation and clinical workup.¹³ If you are receiving IVIG, make sure your doctor knows, because the timing of blood draws relative to infusions can affect the result.

Therapeutic monoclonal antibodies present a newer challenge. Daratumumab, widely used in myeloma treatment, is itself an IgG-kappa antibody. It can appear as its own band on SPEP and IFE, and when a patient’s endogenous M-protein also happens to be IgG-kappa, the two can co-migrate and become indistinguishable on standard tests. Pharmacokinetic studies show daratumumab peak plasma concentrations can reach up to 1 g/L, and the drug can add up to 0.20 g/dL on SPEP quantification.¹⁴ This interference can mask the clearance of the disease M-protein by IFE, which is required for classification of a complete response.¹⁵ A specialized reflex assay called DIRA (or Hydrashift) uses an anti-daratumumab antibody to shift or remove the drug’s band, revealing whether the patient’s own M-protein is still present underneath.¹⁶

What the Numbers Mean for Treatment Response

Doctors use standardized criteria from the International Myeloma Working Group (IMWG) to classify how well treatment is working. The M-spike value is central to these categories. Response is graded by how much the serum M-protein drops from its baseline (the value at the start of treatment). A partial response (PR) requires at least a 50% reduction, while a very good partial response (VGPR) requires at least a 90% reduction. Complete response (CR) requires a negative IFE in addition to the M-spike becoming undetectable by SPEP.¹⁷

Because response hinges on percentage change from baseline, the accuracy and consistency of M-spike measurements over time are critical. Even modest measurement variability can shift a patient from one response category to another, especially near the thresholds. That is another reason why switching labs or quantification methods mid-treatment is something to avoid if possible.

Serial monitoring of M-spike, free light chain ratios, and (where applicable) urine M-spike is the standard approach. Each of these markers has its own normal biological variation even in patients whose disease is clinically stable, which means small fluctuations between visits do not necessarily signal disease progression.¹⁸ Doctors typically look for a sustained trend rather than acting on a single measurement.

Oligoclonal Bands After Treatment

Something that can confuse patients reviewing their own lab results is the appearance of new, small bands on electrophoresis after treatment. These oligoclonal bands (OBs) represent the immune system reconstituting itself, with small clones of recovering B cells temporarily producing detectable immunoglobulin. They are not the same as the original M-spike and generally are not a sign of relapse.

In a study of 163 myeloma patients, about a quarter developed oligoclonal bands after treatment. Detection rates were highest in patients who achieved a complete response (about 52%) and lower in those with a very good partial response (about 36%), with none appearing in patients with only a partial response or less.¹⁹ While the presence of oligoclonal bands correlated with better outcomes in the overall group, that survival advantage disappeared when the comparison was restricted to patients who had already achieved a deep response. In other words, oligoclonal bands may simply be a marker of good response depth rather than an independent positive sign.

Mass Spectrometry and the Future of M-Protein Detection

Conventional SPEP and IFE have limits. They cannot reliably detect very low levels of residual monoclonal protein, which matters increasingly as treatments improve and more patients achieve deep responses where the M-spike disappears from standard tests. Mass spectrometry is emerging as a much more sensitive alternative. It can detect and quantify monoclonal proteins in blood with sensitivity several orders of magnitude greater than conventional SPEP and IFE.²⁰

Both “top-down” approaches (which analyze intact light chains) and “bottom-up” approaches (which identify clonotypic peptide fragments unique to the patient’s monoclonal protein) have shown sensitivity comparable to or even surpassing bone marrow-based methods like next-generation flow cytometry or sequencing. This is a significant development because it means a blood test could potentially replace or supplement the invasive bone marrow biopsy for assessing minimal residual disease. Mass spectrometry is not yet part of routine clinical practice for most patients, but it is increasingly available at academic medical centers and is likely to become standard in the coming years.

Tracking M-Spike Changes in MGUS

Not everyone with an M-spike has myeloma. Monoclonal gammopathy of undetermined significance (MGUS) is far more common and, by definition, involves a small M-protein without evidence of organ damage or other myeloma-defining events. MGUS requires ongoing monitoring because a small percentage of patients progress to myeloma or a related malignancy each year.

A cohort study that followed MGUS patients over time found that progression patterns varied. Some patients showed a slow, steady rise in M-spike, while others had a rapid clonal expansion closer to the time of myeloma diagnosis. Among patients initially classified as low-risk MGUS, the median annual increase in M-spike after a follow-up blood draw was 6.0 g/L, compared with 2.2 g/L in patients with other risk profiles, though the difference was not statistically significant given the small sample.²¹ The finding hints that even patients with initially reassuring risk features can experience rapid M-spike acceleration, underscoring why regular monitoring matters regardless of risk category.

Updated diagnostic criteria have also changed how M-spike levels feed into clinical decisions. Since 2014, the IMWG expanded its criteria for myeloma to include biomarkers that can flag active disease before organ damage occurs, meaning that the M-spike value is interpreted alongside bone marrow plasma cell percentages, free light chain ratios, and imaging findings rather than in isolation. A rising M-spike in the absence of symptoms does not automatically trigger treatment, but it intensifies surveillance and may prompt additional testing to look for early signs of progression.